Benjamin P. Saylor

“You have to be balanced in what to embrace vs what not. It is easy to be wowed by new things," said Scott Eggener, MD.

"We found that the new TENACIO pump was able to complete tasks faster and more efficiently compared to the older MS pump," says Justin Lee, MD.

68.8% of patients had at least a 30% improvement in ventral curvature from baseline.

“The take-home message…is it doesn't matter whether you put the reservoir in the ectopic location or the prevesical location. Patients tend to be satisfied in both locations,” said Mohit Khera, MD, MBA, MPH.

The investigators reported a significantly greater prevalence of ED in men with BPH (P < .0001).

For the survey question “Do 5-ARIs reduce serum PSA?” 8 (9.4%) respondents said “no” and 25 (29.4%) said “not sure.”

Following use of MED3000, the investigators reported significant improvements in all 5 SEP questions in both patients and partners over the course of the 12 weeks.

The investigators reported a significant improvement in IPSS, from 21.9 at baseline to 12.6 at 4 years.

“Initiating oral TU therapy with Kyzatrex at 400 mg BID is safe and effective in achieving therapeutic serum testosterone levels," wrote the authors.

The investigators found that only 2 (1.4%) urology programs and 12 (5.3%) OB/GYN programs included female sexual dysfunction content.

“In the absence of infection, [drain and retain] is a safe strategy without further complications compared to the primary groups," said Thairo Pereira, MD.

“Before and after implant, we noted a statistically significant increase in both the length and the girth,” said Peter J. Arnold, MD.

According to iota Biosciences, the device is “designed to deliver electrical stimulation directly to the bladder wall, inducing contractions that facilitate bladder emptying in individuals impacted by underactive bladder.”

"The TALAPRO-2 results provide much-needed hope to patients who remain in high unmet need for effective treatment options," said Neeraj Agarwal, MD, FASCO.

"The addition of radium-223 to SABR metastasis-directed therapy in low-volume bone-metastatic hormone-sensitive prostate cancer does not delay progression of disease in the RAVENS study," said Ana Kiess, MD, PhD.

Overall, a total of 693 patients received a PEG spacer in 2017 and 2510 received one in 2022, an increase of 262%.

“Pembrolizumab maintenance therapy after SABR boost to bladder tumor and concurrent radio-chemotherapy was well tolerated with promising efficacy in the early analysis," said Shang-bin Qin, MD.

“At a median follow-up of 37 months, we saw that failure-free survival was statistically significant, with 2 times more events seen in the control arm," said Colin Belliveau, MD.

“Patients in the darolutamide arm did not reach first [radiological progression-free survival] median, but at 24 months, 70[.3]% had not progressed vs 52[.1]% in the placebo/ADT arm,” said Fred Saad, CQ, MD, FRCS, FCAHS.

“There is no clear evidence that adding metformin to standard of care increases overall survival in unselected patients with metastatic hormone-sensitive disease," said Silke Gillessen, MD.

Andrea Necchi, MD, reported that pCR was 42% (95% CI, 28-56) in cohort 1 and 23% (95% CI, 10-41) in cohort 2.

In the experimental arm, 41% of patients had an undetectable PSA level at week 48 vs 16% in the control arm (OR=3.88; 95% CI, 1.61-9.38, P = .002).

“What we’ve shown is [EV/pembrolizumab] outperforming chemotherapy in all subgroups," says Thomas B. Powles, MBBS, MRCP, MD.

According to the authors, “darolutamide significantly reduced the risk of radiological progression or death by 46%” (HR=0.54, 95% CI, 0.41-0.71, P < .0001).

“The overall survival showed a 25% reduction in the risk of death. This is statistically significant,” said Thomas B. Powles, MBBS, MRCP, MD.

At a median follow-up of 44.8 months, median DFS in the pembrolizumab arm was 29.6 months vs 14.2 months in the observation arm.

The results “support the prioritized development of TAR-200 monotherapy in patients with BCG-unresponsive high-risk non–muscle-invasive bladder cancer," said Michiel van der Heijden, MD, PhD.

Median OS was 35.0 months in the enzalutamide-alone arm vs 42.3 months in the combination arm.

“NKT2152 demonstrated robust anti-tumor activity in a heavily pretreated, high-risk advanced clear cell renal cell carcinoma population," said Eric Jonasch, MD.

"These final analysis results of LITESPARK-005 support belzutifan as a treatment option in refractory kidney cancer after checkpoint inhibitor and VEGFR-TKI therapy," says Brian Rini, MD.